A total of 193,411 shares changed hands on the counter till 10:39AM (IST).
Buy Bharti Hexacom, target price Rs 1,737: HDFC Securities (01-10-2024)
HDFC Securities has buy call on Bharti Hexacom with a target price of Rs 1,737. The current market price of Bharti Hexacom is Rs 1,425.65.
Stock market update: Nifty Pharma index falls 0.68% in a weak market (01-10-2024)
The Nifty Pharma index was trading 0.68 per cent down at 23122.3.
Shakti Pumps – solar shakti (power)! (01-10-2024)
Isn’t this the whole point of a Bonus issue? Most retail investors feel they are getting something for “free” and also when the price reduces most investors who shy away thinking a 4500 share is an expensive bet come back at 900 considering it cheaper. As the market works on what “Most” of the investors think…bonus always works wonders to bring back the lost charm of a stock.
Shriram Finance shares rise 0.35% as Sensex slides (01-10-2024)
A total of 2,945 shares changed hands on the counter till 10:34AM (IST)
What do the latest Sebi moves mean for the market? Sunil Subramaniam answers (01-10-2024)
Sunil Subramaniam discusses SEBI’s push to expand the registered investment advisor (RIA) framework to enhance investor protection and market participation. New regulations aim to bridge gaps in mutual fund accessibility, improve investor alignment, and introduce a regulated framework for F&O traders, potentially reducing investment risks and promoting fund manager expertise.
Stock market update: Sugar stocks up as market falls (01-10-2024)
The 30-share BSE Sensex was down 116.8 points at 84182.98
Tech Mahindra shares zoom 4% after CLSA upgrades stock to outperform, hikes TP to Rs 1,749 (01-10-2024)
Shares of Tech Mahindra surged 4.2% to Rs 1,642.20 on the BSE after CLSA upgraded the stock to ‘outperform’ from ‘hold’ with a target price of Rs 1,749. The upgrade follows recent price correction and early signs of EBIT margin improvement, despite lackluster order bookings.
Sun Pharma inks exclusive pact with Philogen for commercializing anti-cancer drug Fibromun (01-10-2024)
Sun Pharmaceutical Industries said that it has entered into a global exclusive commercialization, license, and supply agreement with Philogen for commercializing the latter’s specialty product Fibromun.